Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
The company dribbles out more data on IMA203, and the numbers head in the right direction.
ASCO is fast approaching, but in the meantime Olema will have an important readout.
The sale of remaining rights to Allogene ends acrimony between the two companies.
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.
Keyvibe-010 fails, but not for the reason you might have expected.
Tamarack data reveal vobra-duo’s toxicity, and wipe out the past six months’ share price gains.